science
중도 성향
STAT+: A standing ovation for RevMed, and caution for Akeso
STAT News
조회 0
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy. ...
관련 뉴스
관련 뉴스 제보는 로그인 후 가능합니다.
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy. ...